Insight Into the Cellular Activities of Tranexamic Acid as an Option for Melasma Treatment
Cell Biology International · 2026
DOI: 10.1002/cbin.70097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology International, 2026. Verfasst von Yekatsiaryna Hushcha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Morgan S.r.l., R&D, Monteviale (VI), Italy. Hauptthemen laut MEDLINE: Tranexamic Acid, Melanosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: This study was supported by the University of Ferrara FAR (2020) and PRIN 2017; Morgan Srl, Monteviale (VI), Italy; Associazione Italiana per la Ricerca sul Ca….
Abstract (Originalsprache)
Melasma and other hyperpigmentation disorders represent a significant challenge in dermatology. Tranexamic acid (TXA), traditionally known for its antifibrinolytic activity via inhibition of plasminogen activation, has recently emerged as a promising depigmenting agent. However, its cellular effects on skin cells involved in melanogenesis remain poorly understood. In this study, we investigated TXA's impact on melanocytes, keratinocytes, and inflammatory cells. TXA directly inhibited melanin synthesis in B16 melanoma cells, with an additive effect when combined with α‐arbutin. In keratinocytes and macrophages, TXA attenuated inflammatory responses triggered by the plasminogen/plasmin (Plg/Plm) pathway. Moreover, TXA reduced lipopolysaccharide‐induced pro‐inflammatory gene expression in mouse macrophages, suggesting interference with Toll‐like receptor‐mediated inflammation. These findings highlight TXA's multifaceted actions on skin cells involved in pigmentation and support its therapeutic potential in melasma and potentially other skin diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Morgan S.r.l., R&D, Monteviale (VI), Italy.
- Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
- Department of Medical Sciences, Center for Studies on Gender Medicine, University of Ferrara, Ferrara, Italy.
- Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
- Centralized Laboratory of Pre-Clinical Research, University of Ferrara, Ferrara, Italy.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Anna Lisa Giuliani, Martini Fernanda, Ilaria Bononi, Chiara Mazziotta, John Charles Rotondo, Monica De Mattei
Förderung
- This study was supported by the University of Ferrara FAR (2020) and PRIN 2017; Morgan Srl, Monteviale (VI), Italy; Associazione Italiana per la Ricerca sul Ca…
Zitieren
APA
Hushcha, Y., Giuliani, A. L., Fernanda, M., Bononi, I., Mazziotta, C., Rotondo, J. C., & De Mattei, M. (2026). Insight Into the Cellular Activities of Tranexamic Acid as an Option for Melasma Treatment. Cell Biology International. https://doi.org/10.1002/cbin.70097
Vancouver
Hushcha Y, Giuliani AL, Fernanda M, Bononi I, Mazziotta C, Rotondo JC, et al. Insight Into the Cellular Activities of Tranexamic Acid as an Option for Melasma Treatment. Cell Biology International. 2026. doi:10.1002/cbin.70097
BibTeX
@article{Hushcha2026,
author = {Hushcha, Yekatsiaryna and Giuliani, Anna Lisa and Fernanda, Martini and Bononi, Ilaria and Mazziotta, Chiara and Rotondo, John Charles and De Mattei, Monica},
title = {Insight Into the Cellular Activities of Tranexamic Acid as an Option for Melasma Treatment},
journal = {Cell Biology International},
year = {2026},
doi = {10.1002/cbin.70097}
}
EUVIMED